Health Technology Shionogi & Co., Ltd. Business Summary
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 297,177M 2,802.03M Gross Profit 238,000M 2,244.06M Operating income 95,694M 902.28M Income before tax 143,018M 1,348.49M Net income 111,858M 1,054.69M EBITDA 110,403M 1,040.97M Diluted EPS 364.88 3.44 Dividends Per Share 108 1.01 Total Assets 998,992M 9,040.65M Total liabilities 134,156M 1,214.08M Total equity 846,108M 7,657.08M Operating cash flow 109,039M 1,028.11M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
338,890M
344,667M
367,960M
333,371M
297,177M
Gross Profit
261,113M
270,756M
305,713M
270,117M
238,000M
Operating income
108,179M
115,219M
168,370M
130,609M
95,694M
Income before tax
122,695M
137,378M
174,043M
158,516M
143,018M
Net income
83,878M
108,866M
137,190M
122,193M
111,858M
EBITDA
124,519M
134,226M
187,074M
144,649M
110,403M
Diluted EPS
255.87
337.42
434.70
395.28
364.88
Dividends Per Share
72
82
94
103
108
Total Assets
670,271M
711,463M
938,540M
873,695M
998,992M
Total liabilities
144,058M
106,619M
125,125M
108,186M
134,156M
Total equity
522,737M
601,374M
808,774M
765,152M
846,108M
Operating cash flow
111,903M
129,790M
165,000M
131,940M
109,039M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
3,129.53M
3,109.80M
3,318.10M
3,066.16M
2,802.03M
Gross Profit
2,411.29M
2,442.93M
2,756.78M
2,484.38M
2,244.06M
Operating income
998.99M
1,039.57M
1,518.28M
1,201.26M
902.28M
Income before tax
1,133.04M
1,239.51M
1,569.44M
1,457.94M
1,348.49M
Net income
774.58M
982.25M
1,237.11M
1,123.86M
1,054.69M
EBITDA
1,149.89M
1,211.07M
1,686.95M
1,330.40M
1,040.97M
Diluted EPS
2.36
3.04
3.92
3.63
3.44
Dividends Per Share
0.66
0.73
0.84
0.94
1.01
Total Assets
6,015.17M
6,689.82M
8,479.37M
8,093.14M
9,040.65M
Total liabilities
1,292.81M
1,002.52M
1,130.46M
1,002.13M
1,214.08M
Total equity
4,691.16M
5,654.66M
7,306.98M
7,087.69M
7,657.08M
Operating cash flow
1,033.38M
1,171.04M
1,487.89M
1,213.51M
1,028.11M
Valuation Measures
Mar 2021
PER 16.30 ROA 11.94% ROE 13.88% Operating margin 32.20% Profit margin 37.64%
Key executives
President & Representative Director:
Isao Teshirogi
Director & Executive Vice President:
Takuko Sawada
Executive Officer:
Takeshi Shiota
Executive Officer:
Miyuki Hiura
Executive Officer & Personnel Manager:
Noriyuki Kishida Shareholders
Nomura Asset Management Co., Ltd. (6.8%)
Sumitomo Life Insurance Co. (5.9%)
Shionogi & Co., Ltd. (3.2%)
Sumitomo Mitsui Banking Pension Fund (3.0%)
Nikko Asset Management Co., Ltd. (2.8%)
Daiwa Asset Management Co. Ltd. (2.8%)
Nippon Life Insurance Co. (2.6%)
The Vanguard Group, Inc. (2.3%)
Ping An Insurance (Group) Co. of China Ltd. (2.0%)
Capital International KK (1.9%)
Related Companies
Shionogi Singapore Pte Ltd.
Shionogi Marketing Solutions Co., Ltd.
Shionogi Pharmacovigilance Center Co., Ltd.
Shionogi Business Partner Co., Ltd.
Shionogi Digital Science Co., Ltd
Shionogi Career Development Center Co., Ltd.
Shionogi TechnoAdvance Research Co., Ltd.
Shionogi BV
Shionogi Pharma Co., Ltd.
Shionogi Healthcare Co. Ltd.
Shionogi & Co., Ltd. /2 Subsidiaries/
Shionogi & Co. Restricted Stock Compensation Plan
Shionogi Healthcare & Co., Ltd.
Pionnier KK
Shionogi USA Holdings, Inc.
Beijing Shionogi Pharmaceutical Technology Ltd.
Shionogi Ltd.
Ezose Sciences, Inc.
Shionogi, Inc.
Shionogi Institute for Medical Science
Aburahi Laboratories
Taiwan Shionogi & Co., Ltd.
Shionogi Pharma Chemicals Co., Ltd.
Shionogi General Service Co., Ltd.
Shionogi Bunseki Center KK
Shionogi Ireland Ltd.
Shionogi Engineering Service Co. Ltd.
UMN Pharma, Inc.
Shionogi Bioresearch Corp.
Shionogi & Co. Ltd. Pension Fund
Competitors
CytoDyn Inc.
Vaxart, Inc.
NanoViricides, Inc.
Entasis Therapeutics Holdings, Inc.
Trevi Therapeutics, Inc.
Nabriva Therapeutics Plc
Spero Therapeutics, Inc.
TaiMed Biologics Inc.
BioCryst Pharmaceuticals, Inc.
Cocrystal Pharma Inc
Iterum Therapeutics plc
Vir Biotechnology, Inc.
Acura Pharmaceuticals, Inc.
aTyr Pharma, Inc.
Arbutus Biopharma Corporation
BELLUS Health Inc.
Surface Oncology, Inc.
Terns Pharmaceuticals, Inc.
Zynerba Pharmaceuticals Inc
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 18 May, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close